Company news
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news
Atara Biotherapeutics, Inc. news releases on 6ix. Latest, Dec 8, 2020: Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
Press releases — page 3
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
December 7, 2020
Atara Biotherapeutics Announces Proposed Offering of Common Stock
December 6, 2020
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
November 11, 2020
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
November 8, 2020
Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
November 1, 2020
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
September 10, 2020
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
September 7, 2020
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
August 4, 2020
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 23, 2020
Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
June 16, 2020
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
June 4, 2020
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
May 26, 2020
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
May 25, 2020
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020
May 14, 2020
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
May 13, 2020
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
May 10, 2020
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
May 5, 2020
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
April 29, 2020
Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
April 1, 2020
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
February 26, 2020
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
February 18, 2020
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
February 4, 2020
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
November 6, 2019
Atara Biotherapeutics Announces Executive Departures
October 24, 2019